Pharmacokinetics of CS-023 (RO4908463), a Novel Parenteral Carbapenem, in Healthy Male Caucasian Volunteers
- 1 December 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (12) , 4186-4188
- https://doi.org/10.1128/aac.00494-06
Abstract
The CS-023 concentration in plasma after administration by infusion to healthy volunteers at a dose of 700 mg was decreased, with a half-life of 1.7 h, and the cumulative urinary excretion was 59.4% of the dose. The total clearance, renal clearance, and volume of distribution were 8.12 liters/h, 4.14 liters/h, and 17.2 liters, respectively.Keywords
This publication has 14 references indexed in Scilit:
- In Vitro and In Vivo Antibacterial Activities of CS-023 (RO4908463), a Novel Parenteral CarbapenemAntimicrobial Agents and Chemotherapy, 2005
- CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosaJournal of Antimicrobial Chemotherapy, 2004
- Prevention of Resistance: A Goal for Dose Selection for Antimicrobial AgentsClinical Infectious Diseases, 2003
- Comparative Pharmacokinetics of the CarbapenemsClinical Pharmacokinetics, 2000
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- The Pharmacology of Meropenem, A New Carbapenem AntibioticClinical Infectious Diseases, 1997
- Methods of Determining Plasma and Tissue Binding of DrugsClinical Pharmacokinetics, 1992
- Interactions in vitro between agents used to treat melioidosisJournal of Antimicrobial Chemotherapy, 1989
- The pharmacokinetics of meropenem in volunteersJournal of Antimicrobial Chemotherapy, 1989
- Pharmacokinetic profile of lmipenem/cilastatin in normal volunteersThe American Journal of Medicine, 1985